Appointments, Regulatory Approvals, Conference Participation Schedule, Acquisitions, and Increased Stake - Analyst Notes on

    Appointments, Regulatory Approvals, Conference Participation Schedule,
 Acquisitions, and Increased Stake - Analyst Notes on Perrigo, Zoetis, ISIS,
                             GSK, and AstraZeneca

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, March 13, 2014

NEW YORK, March 13, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Perrigo Company
(NYSE: PRGO), Zoetis Inc. (NYSE: ZTS), ISIS Pharmaceuticals, Inc. (NASDAQ:
ISIS), GlaxoSmithKline plc (NYSE: GSK), and AstraZeneca plc (NYSE: AZN).
Private wealth members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:


Perrigo Company Analyst Notes

On February 28, 2014, Perrigo Company (Perrigo) reported its acquisition of a
basket of value-brand OTC products sold in Australia and New Zealand from
Aspen Global Inc. for $51 million in cash. According to the Company, the
acquired products include Herron® range of analgesics, vitamins and
supplements, and are expected to generate at least $20 million in annual
revenue. Perrigo's Chairman, President and CEO, Joseph C. Papa said, "The
acquisition of OTC products in Australia enhances our position by broadening
our product offering and increasing our relevance with the mass retail
customers. This deal furthers our strategy to expand our Consumer Healthcare
portfolio internationally, while making quality products more affordable for
consumers and customers around the world." The full analyst notes on Perrigo
Company are available to download free of charge at:


Zoetis Inc Analyst Notes

On March 4, 2014, Zoetis Inc (Zoetis) announced that it has appointed Dr.
Wille M. Reed to its Board of Directors. According to the Company, in his new
role, Dr. Reed will serve on the Corporate Governance Committee of the Board.
Dr. Reed serves as the Dean of the College of Veterinary Medicine at Purdue
University, and has more than 30 years of experience in animal health and
veterinary medicine. The Company stated that as a recognized expert in avian
pathology, diagnostic medicine and infectious diseases, Dr. Reed brings
perspectives on veterinary medicine that will be crucial as Zoetis continues
to enhance its reputation as a world leader in animal health. The Company
believes that Dr. Reed will add valuable scientific expertise to the Zoetis
Board, as well as a unique understanding of the needs of Zoetis customers and
the animals that depend on the company's medicines and vaccines. The full
analyst notes on Zoetis Inc are available to download free of charge at:


ISIS Pharmaceuticals, Inc. Analyst Notes

On March 6, 2014, ISIS Pharmaceuticals, Inc. (ISIS) announced its
participation at the upcoming Barclays Global Healthcare Conference. The
Company informed that the conference will take place on Thursday, March 13,
2014 at 9:00 a.m. ET in Miami, Florida. According to the Company, interested
parties can view the live webcast of the presentation on the "Investors &
Media" section of ISIS' website. The full analyst notes on ISIS
Pharmaceuticals, Inc. are available to download free of charge at:


GlaxoSmithKline plc Analyst Notes

On March 9, 2014, GlaxoSmithKline plc (GSK) announced that the Company has
successfully increased its stake in its publicly-listed pharmaceuticals
subsidiary in India, GlaxoSmithKline Pharmaceuticals Limited, from 50.7% to
75% following the voluntary Open Offer undertaken by its subsidiary,
GlaxoSmithKline Pte Ltd. David Redfern, Chief Strategy Officer, GSK, said, "We
are very pleased with the outcome of this transaction, which further increases
our exposure to a strategically important market. It is a significant vote of
confidence in the future growth prospects of our Pharmaceuticals business in
India and underlines GSK's long-standing commitment to the country." The full
analyst notes on GlaxoSmithKline plc are available to download free of charge


AstraZeneca plc Analyst Notes

On March 3, 2014, AstraZeneca plc (AstraZeneca) announced that its BYDUREON®
Pen (exenatide extended-release for injectable suspension) 2 mg as an adjunct
to diet and exercise to improve glycaemic control in adults with type 2
diabetes, has been approved by the U.S. Food and Drug Administration (FDA).
According to the Company, BYDUREON is the first and only once-weekly medicine
for adults with type 2 diabetes, and is a pre-filled, single-use pen injector,
eliminating the need for the patient to transfer the medication between a vial
and syringe during the self-injection process. AstraZeneca informed that the
BYDUREON Pen contains the same formulation and dose as the original BYDUREON
single-dose tray, providing the same continuous release of exenatide. The full
analyst notes on AstraZeneca plc are available to download free of charge at:


About Analysts Review
We provide our members with a simple and reliable way to leverage our economy
of scale. Most investors do not have time to track all publicly traded
companies, much less perform an in-depth review and analysis of the
complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.




  oThis is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
  oInformation in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
  oThis information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
  oIf you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at pubco [at]
  oFor any urgent concerns or inquiries, please contact us at compliance [at]
  oAre you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to research [at] for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Analysts Review. An
outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Analysts Review in this article or
report according to the Procedures outlined by Analysts Review. Analysts
Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.


Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.


Analysts Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Analysts Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Analysts Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA

SOURCE Analysts Review

Contact: CONTACT PERSON: Adam Redford CONTACT PHONE: +852-8191-3972
Press spacebar to pause and continue. Press esc to stop.